Infectious mononucleosis, immune genotypes, and non-Hodgkin lymphoma (NHL): an InterLymph Consortium study

Brown Wadé, N. et al. (2020) Infectious mononucleosis, immune genotypes, and non-Hodgkin lymphoma (NHL): an InterLymph Consortium study. Cancer Causes and Control, 31, pp. 451-462. (doi: 10.1007/s10552-020-01266-4) (PMID:32124188) (PMCID:PMC7534692)

[img] Text
207424.pdf - Accepted Version

609kB
[img]
Preview
Text
207424Suppl.pdf - Supplemental Material

122kB

Abstract

Purpose: We explored the interaction between non-Hodgkin lymphoma (NHL), infectious mononucleosis (IM) history, and immune-related genotypes in a pooled case–control analysis. Methods: A total of 7,926 NHL patients and 10,018 controls from 12 case–control studies were included. Studies were conducted during various time periods between 1988 and 2008, and participants were 17–96 years of age at the time of ascertainment/recruitment. Self-reported IM history and immune response genotypes were provided by the InterLymph Data Coordinating Center at Mayo Clinic. Odds ratios (OR) were estimated using multivariate logistic regression, and interactions were estimated using the empirical Bayes method. PACT was used to account for multiple comparisons. Results: There was evidence of an interaction effect between IM history and two variants on T-cell lymphoma (TCL) risk: rs1143627 in interleukin-1B (IL1B) (pinteraction = 0.04, ORinteraction = 0.09, 95% confidence interval [CI] 0.01, 0.87) and rs1800797 in interleukin-6 (IL6) (pinteraction = 0.03, ORinteraction = 0.08, 95% CI 0.01, 0.80). Neither interaction effect withstood adjustment for multiple comparisons. There were no statistically significant interactions between immune response genotypes and IM on other NHL subtypes. Conclusions: Genetic risk variants in IL1B and IL6 may affect the association between IM and TCL, possibly by influencing T-cell activation, growth, and differentiation in the presence of IM, thereby decreasing risk of immune cell proliferation.

Item Type:Articles
Additional Information:his work was supported by awards from National Cancer Institute/National Institutes of Health (N01-CN-75014-20, P30CA014089, R01 CA186646, P30 CA13148, R21 CA155951, U54 CA118948, CA45614, CA87014, CA104682, and CA154643); Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR), CERCA Programme/Generalitat de Catalunya for institutional support (2017SGR1085); Spanish Ministry of Economy and Competitiveness—Carlos III Institute of Health cofunded by FEDER funds/European Regional Development Fund (ERDF)—a way to build Europe (PI14/01219); Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP, Spain); the Canadian Institutes for Health Research (CIHR); Canadian Cancer Society; and Michael Smith Foundation for Health Research [British Columbia]). The collection of cancer incidence data used in the UCSF study was supported by the California Department of Public Health pursuant to California Health and Safety Code Section 103885; Centers for Disease Control and Prevention’s (CDC) National Program of Cancer Registries, under cooperative agreement 5NU58DP003862-04/DP003862; and the National Cancer Institute’s Surveillance, Epidemiology, and End Results Program under contract HHSN261201000140C awarded to the Cancer Prevention Institute of California, contract HHSN261201000035C awarded to the University of Southern California (NHL MultiCenter Case–Control Study site), and contract HHSN261201000034C awarded to the Public Health Institute.
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Jarrett, Professor Ruth
Authors: Brown Wadé, N., Chang, C. M., Conti, D., Millstein, J., Skibola, C., Nieters, A., Wang, S. S., De Sanjose, S., Kane, E., Spinelli, J. J., Bracci, P., Zhang, Y., Slager, S., Wang, J., Hjalgrim, H., Ekstrom Smedby, K., Brown, E. E., Jarrett, R. F., and Cozen, W.
College/School:College of Medical Veterinary and Life Sciences > School of Infection & Immunity
College of Medical Veterinary and Life Sciences > School of Infection & Immunity > Centre for Virus Research
Journal Name:Cancer Causes and Control
Publisher:Springer
ISSN:0957-5243
ISSN (Online):1573-7225
Published Online:02 March 2020
Copyright Holders:Copyright © Springer Nature Switzerland AG 2020
First Published:First published in Cancer Causes and Control 31:451-462
Publisher Policy:Reproduced in accordance with the publisher copyright policy

University Staff: Request a correction | Enlighten Editors: Update this record